Dietary extra virgin olive oil attenuates kidney injury in pristane-induced SLE model via activation of HO-1/Nrf-2 antioxidant pathway and suppression of JAK/STAT, NF-κB and MAPK activation

Journal of Nutritional Biochemistry

Volumn 27, Issue , 2016, Pages 278-288

  Aparicio Soto, Marina ^a   Sánchez Hidalgo, Marina ^a   Cárdeno, Ana ^a   Rosillo, María Ángeles ^a   Sánchez Fidalgo, Susana ^a   Utrilla, Jose ^b   Martín Lacave, Inés ^b   Alarcón de la Lastra, Catalina ^a  

^a UNIVERSITY OF SEVILLE   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

Author keywords

EVOO; Immunomodulation; Inflammation; Polyphenols; SLE

Indexed keywords

ALCOHOL DERIVATIVE; EXTRA VIRGIN OLIVE OIL; FATTY ACID; HEME OXYGENASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 6; JANUS KINASE; MITOGEN ACTIVATED PROTEIN KINASE; PRISTANE; PROSTAGLANDIN E SYNTHASE 1; PROSTAGLANDIN E2; SODIUM CHLORIDE; SQUALENE; STAT3 PROTEIN; STEROL; STROMELYSIN; SUNFLOWER OIL; TOCOPHEROL; TRANSCRIPTION FACTOR NRF2; TRITERPENE; TUMOR NECROSIS FACTOR ALPHA; ANTIOXIDANT; CYTOKINE; ISOMERASE; NFE2L2 PROTEIN, MOUSE; OLIVE OIL; PROSTAGLANDIN E SYNTHASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HISTOLOGY; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; MOUSE; MOUSE MODEL; NONHUMAN; PROSTAGLANDIN SYNTHESIS INHIBITION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN; SPLEEN CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; COMPLICATION; DISEASE MODEL; KIDNEY DISEASES; METABOLISM;

ANIMALS; ANTIOXIDANTS; CYTOKINES; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; HEME OXYGENASE-1; INTRAMOLECULAR OXIDOREDUCTASES; KIDNEY DISEASES; LUPUS ERYTHEMATOSUS, SYSTEMIC; MAP KINASE SIGNALING SYSTEM; MICE; MICE, INBRED BALB C; NF-E2-RELATED FACTOR 2; NF-KAPPA B; OLIVE OIL; PROSTAGLANDIN-E SYNTHASES;

EID: 84952862664     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2015.09.017     Document Type: Article

References (79)

1. Yu C., Gershwin M.E., Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014, 48-49:10-13.
2. Koutsokeras T., Healy T. Systemic lupus erythematosus and lupus nephritis. Nat Rev Drug Discov 2014, 13:173-174.
3. Kiriakidou M., Cotton D., Taichman D., Williams S. Systemic lupus erythematosus. Ann Intern Med 2013, 159:ITC4-1-14.
4. Caza T., Oaks Z., Perl A. Interplay of infections, autoimmunity, and immunosuppression in systemic lupus erythematosus. Int Rev Immunol 2014, 33:330-363.
5. Navarra S.V., Leynes M.S. Infections in systemic lupus erythematosus. Lupus 2010, 19:1419-1424.
6. Contin-Bordes C., Lazaro E., Pellegrin J.L., Viallard J.F., Moreau J.F., Blanco P. Systemic lupus erythematosus: from pathophysiology to treatment. Rev Med Interne 2009, 30:H9-H13.
7. Crispín J.C., Liossis S.N., Kis-Toth K., Lieberman L.A., Kyttaris V.C., Juang Y.T., et al. Pathogenesis of human systemic lupus erythematosus: recent advances. Trends Mol Med 2010, 16:47-57.
8. Crispín J.C., Kyttaris V.C., Terhorst C., Tsokos G.C. T cells as therapeutic targets in SLE. Nat Rev Rheumatol 2010, 6:317-325.
9. Jones B.M., Liu T., Wong R.W. Reduced in vitro production of interferon-gamma, interleukin-4 and interleukin-12 and increased production of interleukin-6, interleukin-10 and tumour necrosis factor-alpha in systemic lupus erythematosus. Weak correlations of cytokine production with disease activity. Autoimmunity 1999, 31:117-124.
10. Gómez D., Correa P.A., Gómez L.M., Cadena J., Molina J.F., Anaya J.M. Th1/Th2 cytokines in patients with systemic lupus erythematosus: is tumor necrosis factor alpha protective?. Semin Arthritis Rheum 2004, 33:404-413.
11. Wong C.K., Ho C.Y., Li E.K., Lam C.W. Elevation of proinflammatory cytokine (IL-18, IL-17, IL-12) and Th2 cytokine (IL-4) concentrations in patients with systemic lupus erythematosus. Lupus 2000, 9:589-593.
12. van Vollenhoven R.F., Parodis I., Levitsky A. Biologics in SLE: towards new approaches. Best Pract Res Clin Rheumatol 2013, 27:341-349.
13. Cárdeno A., Sánchez-Hidalgo M., Alarcón-de-la-Lastra C. An up-date of olive oil phenols in inflammation and cancer: molecular mechanisms and clinical implications. Curr Med Chem 2013, 20:4758-4776.
14. Sánchez-Fidalgo S., Cárdeno A., Sánchez-Hidalgo M., Aparicio-Soto M., de la Lastra C.A. Dietary extra virgin olive oil polyphenols supplementation modulates DSS-induced chronic colitis in mice. J Nutr Biochem 2013, 24:1401-1413.
15. Alarcón de la Lastra C., Barranco M.D., Motilva V., Herrerías J.M. Mediterranean diet and health: biological importance of olive oil. Curr Pharm Des 2001, 7:933-950.
16. Bulló M., Lamuela-Raventós R., Salas-Salvadó J. Mediterranean diet and oxidation: nuts and olive oil as important sources of fat and antioxidants. Curr Top Med Chem 2011, 11:1797-1810.
17. Urpi-Sarda M., Casas R., Chiva-Blanch G., Romero-Mamani E.S., Valderas-Martínez P., Arranz S., et al. Virgin olive oil and nuts as key foods of the Mediterranean diet effects on inflammatory biomarkers related to atherosclerosis. Pharmacol Res 2012, 65:577-583.
18. Bermudez B., Lopez S., Ortega A., Varela L.M., Pacheco Y.M., Abia R., et al. Oleic acid in olive oil: from a metabolic framework toward a clinical perspective. Curr Pharm Des 2011, 17:831-843.
19. Escrich E., Solanas M., Moral R., Escrich R. Modulatory effects and molecular mechanisms of olive oil and other dietary lipids in breast cancer. Curr Pharm Des 2011, 17:813-830.
20. Escrich E., Moral R., Solanas M. Olive oil, an essential component of the Mediterranean diet, and breast cancer. Public Health Nutr 2011, 14:2323-2332.
21. Sánchez-Fidalgo S., Sánchez de Ibargüen L., Cárdeno A., Alarcón de la Lastra C. Influence of extra virgin olive oil diet enriched with hydroxytyrosol in a chronic DSS colitis model. Eur J Nutr 2012, 51:497-506.
22. Rosillo M., Alcaraz M.J., Sánchez-Hidalgo M., Fernández-Bolaños J.G., Alarcón-de-la-Lastra C., Ferrándiz M.L. Anti-inflammatory and joint protective effects of extra-virgin olive-oil polyphenol extract in experimental arthritis. J Nutr Biochem 2014, 25:1275-1281.
23. Satoh M., Yamagata H., Watanabe F., Nakayama S., Ogasawara T., Tojo T., et al. Development of anti-Sm and anti-DNA antibodies followed by clinical manifestation of systemic lupus erythematosus in an elderly woman with long-standing Sjögren's syndrome. Lupus 1995, 4:63-65.
24. Satoh M., Reeves W.H. Induction of lupus-associated autoantibodies in BALB/c mice by intraperitoneal injection of pristane. J Exp Med 1994, 180:2341-2346.
25. Shaheen V.M., Satoh M., Richards H.B., Yoshida H., Shaw M., Jennette J.C., et al. Immunopathogenesis of environmentally induced lupus in mice. Environ Health Perspect 1999, 107:723-727.
26. Alperovich G., Rama I., Lloberas N., Franquesa M., Poveda R., Gomà M., et al. New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus 2007, 16:18-24.
27. Sheryanna A., Bhangal G., McDaid J., Smith J., Manning A., Foxwell B.M., et al. Inhibition of p38 mitogen-activated protein kinase is effective in the treatment of experimental crescentic glomerulonephritis and suppresses monocyte chemoattractant protein-1 but not IL-1beta or IL-6. J Am Soc Nephrol 2007, 18:1167-1179.
28. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
29. Wang J.X., Tang W., Yang Z.S., Wan J., Shi L.P., Zhang Y., et al. Suppressive effect of a novel water-soluble artemisinin derivative SM905 on T cell activation and proliferation in vitro and in vivo. Eur J Pharmacol 2007, 564:211-218.
30. Leiss H., Niederreiter B., Bandur T., Schwarzecker B., Blüml S., Steiner G., et al. Pristane-induced lupus as a model of human lupus arthritis: evolvement of autoantibodies, internal organ and joint inflammation. Lupus 2013, 22:778-792.
31. Drappa J., Kamen L.A., Chan E., Georgiev M., Ashany D., Marti F., et al. Impaired T cell death and lupus-like autoimmunity in T cell-specific adapter protein-deficient mice. J Exp Med 2003, 198:809-821.
32. de Zubiria Salgado A., Herrera-Diaz C. Lupus nephritis: an overview of recent findings. Autoimmune Dis 2012, 2012:849684.
33. Summers S.A., Odobasic D., Khouri M.B., Steinmetz O.M., Yang Y., Holdsworth S.R., et al. Endogenous interleukin (IL)-17A promotes pristane-induced systemic autoimmunity and lupus nephritis induced by pristane. Clin Exp Immunol 2014, 176:341-350.
34. Fismen S., Mortensen E.S., Rekvig O.P. Nuclease deficiencies promote end-stage lupus nephritis but not nephritogenic autoimmunity in (NZB×NZW) F1 mice. Immunol Cell Biol 2011, 89:90-99.
35. Ganea E., Trifan M., Laslo A.C., Putina G., Cristescu C. Matrix metalloproteinases: useful and deleterious. Biochem Soc Trans 2007, 35:689-691.
36. Suganami T., Mori K., Tanaka I., Mukoyama M., Sugawara A., Makino H., et al. Role of prostaglandin E receptor EP1 subtype in the development of renal injury in genetically hypertensive rats. Hypertension 2003, 42:1183-1190.
37. Lazarus M., Kubata B.K., Eguchi N., Fujitani Y., Urade Y., Hayaishi O. Biochemical characterization of mouse microsomal prostaglandin E synthase-1 and its colocalization with cyclooxygenase-2 in peritoneal macrophages. Arch Biochem Biophys 2002, 397:336-341.
38. Jiang T., Tian F., Zheng H., Whitman S.A., Lin Y., Zhang Z., et al. Nrf2 suppresses lupus nephritis through inhibition of oxidative injury and the NF-κB-mediated inflammatory response. Kidney Int 2014, 85:333-343.
39. Huang S. Regulation of metastases by signal transducer and activator of transcription 3 signaling pathway: clinical implications. Clin Cancer Res 2007, 13:1362-1366.
40. Harada T., Kyttaris V., Li Y., Juang Y.T., Wang Y., Tsokos G.C. Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 2007, 40:1-8.
41. Godfrey D.G., Stimson W.H., Watson J., Belch J.F., Sturrock R.D. Effects of dietary supplementation on autoimmunity in the MRL/lpr mouse: a preliminary investigation. Ann Rheum Dis 1986, 45:1019-1024.
42. Clark W.F., Parbtani A., Naylor C.D., Levinton C.M., Muirhead N., Spanner E., et al. Fish oil in lupus nephritis: clinical findings and methodological implications. Kidney Int 1993, 44:75-86.
43. Bergamo P., Maurano F., Rossi M. Phase 2 enzyme induction by conjugated linoleic acid improves lupus-associated oxidative stress. Free Radic Biol Med 2007, 43:71-79.
44. Rosillo M.A., Sánchez-Hidalgo M., Sánchez-Fidalgo S., Aparicio-Soto M., Villegas I., Alarcón-de-la-Lastra C. Dietary extra-virgin olive oil prevents inflammatory response and cartilage matrix degradation in murine collagen-induced arthritis. Eur J Nutr 2015, [Epub ahead of print].
45. Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol 2001, 1:147-153.
46. Talaat R.M., Mohamed S.F., Bassyouni I.H., Raouf A.A. Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: correlation with disease activity. Cytokine 2015, 72:146-153.
47. Han L., Yang J., Wang X., Li D., Lv L., Li B. Th17 cells in autoimmune diseases. Front Med 2015, 9:10-19.
48. Martin J.C., Baeten D.L., Josien R. Emerging role of IL-17 and Th17 cells in systemic lupus erythematosus. Clin Immunol 2014, 154:1-12.
49. Xing Q., Wang B., Su H., Cui J., Li J. Elevated Th17 cells are accompanied by FoxP3+ Treg cells decrease in patients with lupus nephritis. Rheumatol Int 2012, 32:949-958.
50. Kato H., Perl A. Mechanistic target of rapamycin complex 1 expands Th17 and IL-4+ CD4-CD8- double-negative T cells and contracts regulatory T cells in systemic lupus erythematosus. J Immunol 2014, 192:4134-4144.
51. Avrămescu C., Biciuşcă V., Dăianu T., Turculeanu A., Bălăşoiu M., Popescu S.N., et al. Cytokine panel and histopathological aspects in the systemic lupus erythematosus. Rom J Morphol Embryol 2010, 51:633-640.
52. Kotajima L., Aotsuka S., Fujimani M., Okawa-Takatsuji M., Kinoshita M., Sumiya M., et al. Increased levels of matrix metalloproteinase-3 in sera from patients with active lupus nephritis. Clin Exp Rheumatol 1998, 16:409-415.
53. Gheita T.A., Abdel Rehim D.M., Kenawy S.A., Gheita H.A. Clinical significance of matrix metalloproteinase-3 in systemic lupus erythematosus patients: a potential biomarker for disease activity and damage. Acta Reumatol Port 2015, 40:145-149.
54. Thalhamer T., McGrath M.A., Harnett M.M. MAPKs and their relevance to arthritis and inflammation. Rheumatology (Oxford) 2008, 47:409-414.
55. Wong C.K., Wong P.T., Tam L.S., Li E.K., Chen D.P., Lam C.W. Activation profile of intracellular mitogen-activated protein kinases in peripheral lymphocytes of patients with systemic lupus erythematosus. J Clin Immunol 2009, 29:738-746.
56. Iwata Y., Wada T., Furuichi K., Sakai N., Matsushima K., Yokoyama H., et al. p38 Mitogen-activated protein kinase contributes to autoimmune renal injury in MRL-Fas lpr mice. J Am Soc Nephrol 2003, 14:57-67.
57. Korn T., Bettelli E., Oukka M., Kuchroo V.K. IL-17 and Th17 cells. Annu Rev Immunol 2009, 27:485-517.
58. Aaronson D.S., Horvath C.M. A road map for those who don't know JAK-STAT. Science 2002, 296:1653-1655.
59. Hofmann S.R., Rösen-Wolff A., Tsokos G.C., Hedrich C.M. Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol 2012, 143:116-127.
60. Imig J.D., Breyer M.D., Breyer R.M. Contribution of prostaglandin EP(2) receptors to renal microvascular reactivity in mice. Am J Physiol Renal Physiol 2002, 283:F415-F422.
61. Chae B.S., Shin T.Y., Kim D.K., Eun J.S., Leem J.Y., Yang J.H. Prostaglandin E2-mediated dysregulation of proinflammatory cytokine production in pristane-induced lupus mice. Arch Pharm Res 2008, 31:503-510.
62. Schneider A., Zhang Y., Zhang M., Lu W.J., Rao R., Fan X., et al. Membrane-associated PGE synthase-1 (mPGES-1) is coexpressed with both COX-1 and COX-2 in the kidney. Kidney Int 2004, 65:1205-1213.
63. Herrera-Acosta J., Reyes P.A., López Manay G., Padilla L., Cerdas Calderón M., Ruiz A., et al. Inhibition of prostaglandin synthesis suppresses the renal functional reserve in patients with lupus nephropathy. Rev Invest Clin 1987, 39:107-114.
64. Xie C., Ma L., Liu J., Li X., Pei H., Xiang M., et al. SKLB023 blocks joint inflammation and cartilage destruction in arthritis models via suppression of nuclear factor-kappa B activation in macrophage. PLoS One 2013, 8:e56349.
65. Makarov S.S. NF-kappa B, in rheumatoid arthritis: a pivotal regulator of inflammation, hyperplasia, and tissue destruction. Arthritis Res 2001, 3:200-206.
66. Karin M. Nuclear factor-kappaB in cancer development and progression. Nature 2006, 441:431-436.
67. Okamoto T. NF-kappaB and rheumatic diseases. Endocr Metab Immune Disord Drug Targets 2006, 6:359-372.
68. Aktan F. iNOS-mediated nitric oxide production and its regulation. Life Sci 2004, 75:639-653.
69. Wang G., Pierangeli S.S., Papalardo E., Ansari G.A., Khan M.F. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
70. Sanchez-Fidalgo S., Cardeno A., Sanchez-Hidalgo M., Aparicio-Soto M., Villegas I., Rosillo M.A., et al. Dietary unsaponifiable fraction from extra virgin olive oil supplementation attenuates acute ulcerative colitis in mice. Eur J Pharm Sci 2013, 48(3):572-581.
71. Cardeno A., Sanchez-Hidalgo M., Aparicio-Soto M., Sanchez-Fidalgo S., Alarcon-de-la-Lastra C. Extra virgin olive oil polyphenolic extracts downregulate inflammatory responses in LPS-activated murine peritoneal macrophages suppressing NF kappa B and MAPK signalling pathways. Food Funct 2014, 5:1270-1277.
72. Takeda Y., Takeno M., Iwasaki M., Kobayashi H., Kirino Y., Ueda A., et al. Chemical induction of HO-1 suppresses lupus nephritis by reducing local iNOS expression and synthesis of anti-dsDNA antibody. Clin Exp Immunol 2004, 138:237-244.
73. Herrada A.A., Llanos C., Mackern-Oberti J.P., Carreño L.J., Henriquez C., Gómez R.S., et al. Haem oxygenase 1 expression is altered in monocytes from patients with systemic lupus erythematosus. Immunology 2012, 136:414-424.
74. Sánchez-Fidalgo S., Villegas I., Aparicio-Soto M., Cárdeno A., Rosillo M., González-Benjumea A., et al. Effects of dietary virgin olive oil polyphenols: hydroxytyrosyl acetate and 3, 4-dihydroxyphenylglycol on DSS-induced acute colitis in mice. J Nutr Biochem 2015, 26:513-520.
75. Aparicio-Soto M., Sánchez-Fidalgo S., González-Benjumea A., Maya I., Fernández-Bolaños J.G., Alarcón-de-la-Lastra C. Naturally occurring hydroxytyrosol derivatives: hydroxytyrosyl acetate and 3,4-dihydroxyphenylglycol modulate inflammatory response in murine peritoneal macrophages. Potential utility as new dietary supplements. J Agric Food Chem 2015, 63:836-846.
76. Cárdeno A., Magnusson M.K., Strid H., Alarcón de La Lastra C., Sánchez-Hidalgo M., Ohman L. The unsaponifiable fraction of extra virgin olive oil promotes apoptosis and attenuates activation and homing properties of T cells from patients with inflammatory bowel disease. Food Chem 2014, 161:353-360.
77. Sánchez-Fidalgo S., Villegas I., Rosillo M., Aparicio-Soto M., de la Lastra C.A. Dietary squalene supplementation improves DSS-induced acute colitis by downregulating p38 MAPK and NFkB signaling pathways. Mol Nutr Food Res 2015, 59:284-292.
78. Cardeno A., Sanchez-Hidalgo M., Aparicio-Soto M., Alarcon-de-la-Lastra C. Unsaponifiable fraction from extra virgin olive oil inhibits the inflammatory response in LPS-activated murine macrophages. Food Chem 2014, 147:117-123.
79. de la Lastra Romero C.A. An up-date of olive oil and bioactive constituents in health: molecular mechanisms and clinical implications. Curr Pharm Des 2011, 17:752-753.